Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) were the target of a significant decrease in short interest in January. As of March 14th, there was short interest totalling 1,460,571 shares, a decrease of 20.3% from the February 28th total of 1,832,140 shares, Analyst Ratings News reports. Approximately 8.9% of the shares of the company are sold short. Based on an average daily trading volume, of 208,611 shares, the days-to-cover ratio is currently 7.0 days.Regulus Therapeutics Inc (NASDAQ:RGLS) shares after opening at $7.19 moved to $7.69 on last trade day and at the end of the day closed at $7.64. Company price to sales ratio in past twelve months was calculated as 16.82and price to cash ratio as 2.89. Regulus Therapeutics Inc (NASDAQ:RGLS) showed a negative weekly performance of -15.30%.
RadNet Inc (NASDAQ:RDNT) announced the expiration & the final results of the previously announced cash-tender offer for any & all of the company’s outstanding $200,0000,000 aggregate-principal amount of 10 3/8 percent of Senior Notes that are due 2018 and its related solicitation of the consents to amend the indenture that governs these Notes. The tender offer has expired pursuant to the terms, on April 3, 2014. On 25 March 2014, RadNet Inc (NASDAQ:RDNT) made the payment in cash for all the Notes that were tendered before 5:00 pm NYC time, on 20 March 2014 .As of this Consent Payment Deadline, RadNet had received tenders & consents in respect of the $193,464,000 aggregate principal amount of these Notes, which represents 96.73% of outstanding Notes, all of which had been accepted for purchase. RadNet Inc. (NASDAQ:RDNT) shares advanced 8.36% in last trading session and ended the day on $3.76. RDNT return on assets is 0.30%.RadNet Inc. (NASDAQ:RDNT) yearly performance is 34.29%.
Sarepta Therapeutics Inc. (Nasdaq: SRPT) is developing a drug for Duchenne muscular dystrophy (remember all those Jerry Lewis Telethons?). The CDC estimates the disease affects about one out of every 5,600 to 7,700 males age 5 to 24 in the United States. By age 24, about 9 out of 10 of the 58% still alive at age 24 are wheelchair-bound. Not a pretty picture. Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved up 7.29% in last trading session and was closed at $24.73, while trading in range of $21.75 – 25.41. Sarepta Therapeutics Inc (NASDAQ:SRPT) year to date (YTD) performance is 21.40%.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that data from its lead, first-in-class program AG-221 will be presented at a Clinical Trials Symposium titled “Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors” at the American Association for Cancer Research (AACR) Annual Meeting 2014. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. Agios Pharmaceuticals Inc (NASDAQ:AGIO) weekly performance is 15.84%. On last trading day company shares ended up $45.35. Agios Pharmaceuticals Inc (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 30.59%. Analysts mean target price for the company is $49.00.